G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase III Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
G1 Therapeutics, Inc. announced that the last patient has been randomized in the Phase III clinical trial of trilaciclib for patients with metastatic colorectal cancer receiving chemotherapy.
[Haematologica] Myeloid-derived suppressor cells (MDSCs) populations were evaluated in acquired aplastic anemia in which aberrant immune mechanisms contributed to bone marrow destruction.
[Cell Death & Disease] To investigate the effect of ellagic acid (EA) on benign prostate hyperplasia, scientists used EA, a phytochemical abundant in fruits and vegetables, to treat testosterone propionate-induced BPH rats and RWPE-1 human prostate epithelial cells.